Introduction
============

The hormone-sensitive lipase (HSL) plays an important role in triacylglycerol (the major fuel stored in adipose tissue) catabolism via a hormone-stimulated lipolysis process \[[@B1]\]. Its activity is regulated by catecholamines that induce adenylate cyclase and cyclic adenosine monophosphate (cAMP) formation, which, in turn, activates protein kinase A and a cAMP-mediated phosphorylation of a single serine residue on HSL. Insulin exerts its hypolipidaemic effect by activating a cAMP phosphodiesterase, leading to lower intracellular cAMP concentrations, thereby inhibiting cAMP-dependent protein kinase phosphorylation \[[@B2],[@B3]\]. Thus, in adipose tissue, lipid mobilisation depends on the balance between the stimulatory and inhibitory pathways of HSL activation \[[@B2],[@B4],[@B5]\]. During exercise, lipid mobilisation from adipose tissue is mainly stimulated by increased catecholamine production, leading to enhanced β-adrenoceptor-mediated stimulation of lipolysis \[[@B6]\]. In skeletal muscle, it has been shown that HSL activity is increased at the onset of low to moderate intensity exercise, and is essential for intramuscular triacylglycerol mobilisation, but does not seem to be the only factor responsible for their mobilisation \[[@B7]\].

The hormone-sensitive lipase gene (*LIPE*) is located on chromosome 19 (19q13.2, 52.1 centimorgans)\[[@B8]\] in a region previously shown to be linked to plasma low-density lipoprotein cholesterol (LDL-C) concentrations,\[[@B9]\] plasma triglyceride (TG) levels and adiposity \[[@B10]\] and plasma TG concentrations in families suffering from type 2 diabetes \[[@B11]\]. A *LIPE*C-60G point mutation located in front of the first exon coding for the protein with triacylglycerol lipase activity \[[@B12]\] has been associated with body composition \[[@B13]\] and waist circumference in normal-weight subjects \[[@B14]\]. The rare G-60 allele leads to a 40 per cent reduction in transcriptional activity *in vitro*,\[[@B12],[@B14]\] and has been associated with higher insulin sensitivity in women \[[@B15]\] but higher LDL-C in men \[[@B15],[@B16]\]. It has been proposed that the *LIPE*G-60 allele has opposite effects on glucose homeostasis, protecting against insulin resistance in healthy young men \[[@B17]\] but increasing fasting glucose levels in non-drinker men only \[[@B16]\]. These observations suggest that the effect of the *LIPE*C-60G polymorphism on plasma lipids are gender specific and may vary according to lifestyle habits. A meta-analysis of randomised controlled trials suggested that low-intensity physical activity, such as walking, reduces LDL-C and the total-cholesterol/high-density lipoprotein cholesterol (HDL-C) ratio independently of changes in body composition \[[@B18]\]. Some reports have shown the importance of gene-physical activity interactions on health-related phenotypes \[[@B19]\].

We hypothesised that the effects of the *LIPE*C-60G polymorphism on body fat and plasma lipid and lipoprotein concentrations are dependent on physical activity levels. The aim of the present study was to investigate the effects of the *LIPE*C-60G by physical activity interactions on body composition and plasma lipid and lipoprotein concentrations in subjects participating in the Quebec Family Study (QFS).

Materials and methods
=====================

Subjects
--------

The present study was undertaken using data from the QFS, which involved Caucasian families of French descent living within an 80 km radius of Quebec, as described in detail previously \[[@B20]\]. After exclusion of subjects taking lipid-lowering drugs (statins, fibrates, nicotinic acid), anthropometric information, as well as plasma lipid and lipoprotein concentrations, were available for 862 subjects from 222 nuclear families. The Institutional Review Board of Laval University approved the study protocol, and informed written consent was obtained from each participant.

Anthropometric and abdominal fat area measurements
--------------------------------------------------

Anthropometric variables included body mass index (BMI) \-- computed as weight (kg)/height (m) \-- and percentage body fat (per cent) \-- estimated from body density measurements obtained using the hydrostatic weighing technique \[[@B21]\] and derived from the Siri equation \[[@B22]\]. Fat mass (kg) was calculated from percentage body fat and body weight. Abdominal visceral and total abdominal fat areas were assessed using computed tomography between the fourth and fifth lumbar (L4-L5) vertebrae, as described previously \[[@B23]\]. The abdominal subcutaneous fat area was obtained by calculating the difference between total and abdominal visceral fat areas.

Plasma lipid and lipoprotein measurements
-----------------------------------------

Blood samples were collected in the morning, after a 12-hour overnight fast, from the antecubital vein into vacutainer tubes containing ethylene diamine tetra-acetic acid (EDTA). Blood drawing and determination of plasma lipid and lipoprotein concentrations have been detailed previously \[[@B24]\]. Briefly, cholesterol \[[@B25]\] and TG \[[@B26]\] concentrations were determined enzymatically using a Technicon RA-500 automated analyser (Bayer, Tarrytown, NY, USA). The plasma very-low-density lipoprotein (VLDL) (density \< 1.006 g/ml) fraction was isolated by ultracentrifugation, whereas the HDL fraction was obtained after precipitation of LDL in the infranatant (density \> 1.006 g/ml) with heparin and MnCl~2~\[[@B27]\]. TG and cholesterol levels in the infranatant fraction were measured before and after the precipitation step. Apolipoprotein B (apoB) and apolipoprotein A1 (apoA1) concentrations were measured according to the rocket immunoelectrophoretic method of Laurell,\[[@B28]\] as previously described,\[[@B29]\] in the total plasma, LDL (apoB) and HDL (apoA1) fractions. VLDL-apoB content was derived from the difference between plasma apoB and LDL-apoB concentrations.

Physical activity level
-----------------------

Physical activity level was assessed using a three-day (two week days and one weekend day) activity diary, as described previously \[[@B30]\]. Briefly, each day of the diary was divided into 96 periods of 15 minutes, and for each period subjects were instructed to record their dominant activity, using a list of activities categorised in order of increased energy expenditure (metabolic equivalents), using scores ranging from 1 (resting energy expenditure) to 9 (high-intensity exercise) \[[@B30]\]. In order to assess participation in moderate to strenuous physical activity, we only focused on activities which scored between 5 and 9. The number of 15-minute periods for each of the categories between 5 and 9 was firstly summed over each day and weighted by its own category number. A physical activity score, computed as the average sum of scores between 5 and 9 over three days, was then obtained and used as an indicator of participation in moderate to strenuous physical activities \[[@B31]\].

Molecular analysis
------------------

A mini-sequencing assay was performed in a final volume of 16 μl containing 1.56 μM each of dGTP, ddATP, ddCTP and ddTTP (Amersham Pharmacia Biotech Inc., Baie d\'Urfé, QC, Canada), 3.125 nM of forward (5\'-GGACTCCTGGGTTCTAAG-3\'), reverse (5\'-ATTCCCGTCTCTCAGCTG-3\') and IRDye tag mini-sequencing (5\'-TTTTTTTTTCCTTCCACTCTAGGGCTGAT-3\') primers (LICOR, Lincoln, NE, USA); 0.3 U of ThermoSequenase (Amersham Pharmacia Biotech Inc.) and 0.6x buffer (10x: 260 nM Tris-HCl and 65 mM MgCl~2~at pH 9.5). Following a two-minute denaturation step at 95°C, 30 polymerase chain reaction amplification cycles were performed as follows: denaturation at 95°C for 10 seconds, annealing at 57°C for 30 seconds and extension at 72°C for 5 seconds. The amplicon was 308 base pairs (bp) long. Detection was performed using a LICOR automated sequencer, model 4200.

Statistical analysis
--------------------

All statistical analyses were performed using SAS 8.12 software \[[@B32]\]. Prior to adjustment, the normality of the distribution of each variable was tested and variables not normally distributed were transformed. This was the case for plasma TG and VLDL-TG (log~10~transformation) and physical activity score (square root transformation). Deviation from Hardy-Weinberg equilibrium for the *LIPE*C-60G polymorphism was assessed using a *χ*^2^test (Table [1](#T1){ref-type="table"}).

###### 

Genotype and allele frequencies for *LIPE*C-60G polymorphism in unrelated subjects from the Quebec Family Study

  -----------------------------------------------------------------------------------------------------------------------------------------
  Gene     Polymorphism   Genotype   Genotype frequency   Number of subjects   Allele   Allele frequency   95% CI^a^   Deviation from H-W
  -------- -------------- ---------- -------------------- -------------------- -------- ------------------ ----------- --------------------
                          C-60C      90.21                350                                                          

  *LIPE*   C-60G          C-60G      9.54                 37                   -60C\    0.9497\            0.0154      *χ*^2^= 0.0004,\
                                                                               -60G     0.0503                         df = 1,\
                                                                                                                       *p*= 0.98

                          G-60G      0.26                 1                                                            
  -----------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: H-W, Hardy-Weinberg equilibrium; CI, confidence interval

^a^95 per cent CI for allele frequencies were computed as 1.96SQRT(pq/n), where p is the most common allele frequency, q is the rare allele frequency and n the number of alleles.

Association analyses and tests of interaction were performed on residual scores computed for all subjects using stepwise regression procedures. Each phenotype was regressed on age, separately within each of six age-by-sex groups (\< 30, ≥ 30 to \< 50 and ≥ 50 years), keeping only equation terms that were significant at the 5 per cent level. Abdominal visceral fat and plasma lipid and lipoprotein phenotypes were further adjusted for the effect of fat mass. For adjustment purposes, the outliers, defined as those beyond ± 3 SD for each group, were temporally set aside. The regression parameters were then used to calculate the residuals for all subjects, including the outliers. Regression analyses performed separately in men and women were then used to test the effects of the *LIPE*C-60G polymorphism, physical activity and gene-physical activity interaction on the adjusted phenotypes (residuals). The MIXED procedure was used for carrying out these regression analyses because it provides flexibility for modelling the covariance in the data resulting from the fact that the experimental units (in this case the subjects) can be grouped into clusters (the families) and that data from a common cluster are correlated. By using this procedure, it is thus possible to take into account the non-independence of family members in the association analyses. Variables showing significant evidence of gene-physical activity interaction were then tested for association with the *LIPE*C-60G polymorphism separately in men and women, using the same MIXED model procedure, but this time the association analyses were performed separately in each of the four physical activity-genotype groups (low and high physical activity groups based on the sex-specific median values of physical activity score and carriers versus non-carriers of the G-60 allele) using age-adjusted data. Least square means were extracted and tested for differences between the groups using *t*-tests (Figure [1](#F1){ref-type="fig"}).

![***LIPE*(C-60G)-physical activity score interaction on body mass index (BMI), abdominal visceral fat area, abdominal subcutaneous fat area and plasma cholesterol (C)/high-density lipoprotein cholesterol (HDL-C) ratio in subjects from the Quebec Family Study with low and high physical activity scores (cut-off defined by the median)**. Numbers are number of subjects in each group.](1479-7364-3-2-157-1){#F1}

Results
=======

Body fat and plasma lipid and lipoprotein concentrations
--------------------------------------------------------

Body fat and physical activity variables are summarised in Table [2](#T2){ref-type="table"}. No differences in age or in BMI were observed between men and women from both generations. Fathers, mothers, sons and daughters were, on average, within the overweight range (25 kg/m^2^\< BMI \< 30 kg/m^2^). Women were characterised by having significantly more abdominal subcutaneous fat (mothers: +50 per cent; daughters: +56 per cent), while men exhibited more body fat accumulation in the abdominal visceral region (fathers: +35 per cent; sons: +21 per cent) than their gender counterparts. Daughters exhibited a significantly lower physical activity score (-39 per cent) than sons, while fathers and mothers did not exhibit any difference.

###### 

Body fat and physical activity phenotypes in subjects of the Quebec Family Study

  Phenotype                            Fathers               Mothers                       Sons                  Daughters
  ------------------------------------ --------------------- ----------------------------- --------------------- ----------------------------
  Age (years)                          55.5 ± 10.3 (165)     53.8 ± 12.2 (231)             26.6 ± 9.6 (206)      28.0 ± 10.5 (260)
  **Body fat**                                                                                                   
  BMI (kg/cm^2^)                       28.5 ± 5.9 (163)      28.4 ± 7.9 (228)              26.3 ± 7.0 (205)      26.8 ± 8.8 (258)
  Fat mass (kg)                        23.0 ± 10.7 (122)     27.1 ± 14.2 (156) \*\*        18.0 ± 15.1 (182)     22.4 ± 15.3 (235) \*\*
  Percentage body fat (%)              26.6 ± 7.0 (122)      35.6 ± 8.9 (156) \*\*\*       20.2 ± 10.0 (182)     29.5 ± 10.6 (235) \*\*\*
  Abdominal visceral fat (cm^2^)       173.5 ± 86.2 (108)    128.6 ± 71.0 (156) \*\*\*     90.9 ± 66.0 (137)     75.3 ± 56.8 (184) \*
  Abdominal subcutaneous fat (cm^2^)   237.8 ± 108.9 (108)   357.43 ± 168.0 (156) \*\*\*   209.7 ± 160.7 (137)   327.2 ± 197.6 (184) \*\*\*
  Abdominal total fat (cm^2^)          411.4 ± 173.1 (108)   485.9 ± 225.5 (156) \*\*      300.6 ± 214.5 (137)   402.5 ± 241.3 (184) \*\*\*
  **Physical activity score**          85.4 ± 68.8 (137)     69.4 ± 46.4 (185)             77.0 ± 62.2 (184)     55.5 ± 46.8 (228) \*\*\*

Values represent mean ± standard deviation. Sex differences by generation have been tested on transformed variables, when applicable, using the *t*-test: \* 0.05 ≥ *p*\> 0.01; \*\* 0.01 ≥ *p*\> 0.001; \*\*\* 0.001 ≥ *p*\> 0.0001.

Values in parentheses represent the number of subjects. See text for details.

Abbreviation: BMI, body mass index

Plasma lipid and lipoprotein concentrations are summarised in Table [3](#T3){ref-type="table"}. In both generations, no gender differences were observed in plasma cholesterol levels; however, males of both generations exhibited significantly higher VLDL-TG concentrations (fathers: +28 per cent; sons: +28 per cent) than women. Men had higher apoB concentrations (+14 per cent only in the older generation) in this lipid fraction. As compared to mothers, higher LDL-C (+8 per cent) and LDL-apoB (+11 per cent) concentrations were observed in fathers, but this was not the case in the younger generation (no gender difference). Males of both generations exhibited significantly lower HDL-C concentrations (fathers: -22 per cent; sons: -12 per cent) than females. Finally, men exhibited significantly higher plasma cholesterol/HDL-C ratios (+31 per cent in fathers and +13 per cent in sons) than women, suggesting a greater cardiovascular risk in men.

###### 

Plasma lipid and lipoprotein profile parameters in subjects of the Quebec Family Study

  Phenotype                    Fathers               Mothers                    Sons                  Daughters
  ---------------------------- --------------------- -------------------------- --------------------- --------------------------
  **Cholesterol**                                                                                     
  Plasma (mmol/L)              5.33 ± 0.88 (111)     5.18 ± 0.98 (156)          4.44 ± 0.90 (155)     4.44 ± 0.84 (204)
  LDL (mmol/L)                 3.68 ± 0.79 (111)     3.42 ± 0.85 (156) \*\*     2.94 ± 0.79 (155)     2.89 ± 0.78 (204)
  HDL (mmol/L)                 0.97 ± 0.22 (111)     1.24 ± 0.31 (156) \*\*\*   1.02 ± 0.22 (155)     1.16 ± 0.26 (204) \*\*\*
  **Triglyceride**                                                                                    
  Plasma (mmol/L)              1.83 ± 1.00 (111)     1.57 ± 0.77 (156) \*       1.39 ± 0.72 (155)     1.22 ± 0.56 (204)
  VLDL (mmol/L)                1.24 ± 0.82 (111)     0.97 ± 0.65 (156) \*\*     0.91 ± 0.60 (155)     0.71 ± 0.47 (204) \*\*
  **Apolipoproteins**                                                                                 
  Total apoB (g/L)             1.12 ± 0.22 (111)     1.01 ± 0.24 (156) \*\*\*   0.89 ± 0.23 (155)     0.86 ± 0.19 (205)
  VLDL-apoB (g/L)              0.126 ± 0.069 (111)   0.110 ± 0.058 (155)        0.095 ± 0.050 (154)   0.093 ± 0.047 (204)
  LDL-apoB (g/L)               1.00 ± 0.20 (111)     0.90 ± 0.21 (156) \*\*\*   0.80 ± 0.20 (155)     0.77 ± 0.18 (204)
  apoA1 (g/L)                  1.20 ± 0.17 (111)     1.33 ± 0.20 (156) \*\*\*   1.18 ± 0.16 (155)     1.23 ± 0.17 (205) \*\*
  **Ratios**                                                                                          
  Plasma-C/HDL-C               5.74 ± 1.47 (111)     4.39 ± 1.22 (156) \*\*\*   4.51 ± 1.33 (155)     3.98 ± 1.06 (204) \*\*\*
  VLDL-TG/VLDL-apoB (mmol/g)   10.2 ± 5.0 (111)      9.24 ± 4.68 (155)          10.3 ± 5.9 (154)      8.20 ± 4.85 (204) \*\*\*
  LDL-C/LDL-apoB (mmol/g)      3.68 ± 0.37 (63)      3.87 ± 0.41 (90) \*\*      3.68 ± 0.40 (84)      3.84 ± 0.57 (110) \*
  HDL-C/HDL-apoA1 (mmol/g)     0.81 ± 0.13 (111)     0.93 ± 0.16 (156) \*\*\*   0.87 ± 0.15 (155)     0.94 ± 0.16 (204) \*\*\*

Values represent mean ± standard deviation. Sex difference by generation have been tested on transformed variables, when applicable, using the *t*-test: \* 0.05 ≥ *p*\> 0.01; \*\* 0.01 ≥ *p*\> 0.001; \*\*\* 0.001 ≥ *p*\> 0.0001. Numbers of subjects are in parentheses. See text for details.

Abbreviations: C, cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; VLDL, very-low-density lipoprotein

Allelic frequency
-----------------

Allele and genotype frequencies of *LIPE*C-60G calculated using parental data alone are presented in Table [1](#T1){ref-type="table"}. The genotype frequencies did not deviate from the Hardy-Weinberg expectation (*p*= 0.98). No allelic differences were found between males and females (*χ*^2^= 3.08, *p*= 0.21) or between obese and non-obese subjects (BMI cut off = 30 kg/m^2^) (*χ*^2^= 0.52, *p*= 0.77).

Association between *LIPE*C-60G, body fat and plasma lipid and lipoprotein concentrations
-----------------------------------------------------------------------------------------

The results of association analyses are presented in Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"} for men and women, respectively. These Tables present the *p*-values for the main effects of the gene and physical activity level, as well as for the gene-physical activity interaction. The Tables also present the regression coefficients for interaction between physical activity and *LIPE*genotypes (C-60C and G-carriers), as well as their corresponding *p*-values.

###### 

*LIPE*C-60G and *LIPE*C-60G-physical activity interactions on body fat, and plasma lipid and lipoprotein concentrations in men from the Quebec Family Study

                                       C-60G       PA              C-60C by PA        G-60 by PA      Interaction                        
  ------------------------------------ ----------- --------------- ------------------ --------------- ------------------ --------------- ---------------
  **Body fat**                                                                                                                           
  BMI (kg/cm^2^)                       **0.006**   0.33            -0.2262 ± 0.0888   **0.012**       0.1118 ± 0.0790    0.16            **0.006**
  Fat mass (kg)                        0.098       **0.02**        -0.3107 ± 0.1184   **0.010**       -0.0109 ± 0.0766   0.89            **0.04**
  Percentage body fat (%)              0.69        **0.04**        -0.2322 ± 0.0825   **0.006**       -0.0332 ± 0.0980   0.74            0.13
  Abdominal visceral fat (cm^2^)       0.16        0.15            -0.0898 ± 0.0749   0.23            0.2496 ± 0.0866    **0.005**       **0.005**
  Abdominal subcutaneous fat (cm^2^)   0.52        0.16            -0.1825 ± 0.0752   **0.02**        -0.0059 ± 0.1169   0.96            0.23
  Abdominal total fat (cm^2^)          0.30        0.20            -0.1612 ± 0.0702   **0.02**        -0.0332 ± 0.1392   0.81            0.43
  **Cholesterol**                                                                                                                        
  Plasma (mmol/L)                      0.27        0.68            -0.0506 ± 0.0733   0.49            0.1667 ± 0.2741    0.54            0.45
  LDL (mmol/L)                         0.27        0.34            -0.0439 ± 0.0710   0.54            0.2820 ± 0.2443    0.25            0.21
  HDL (mmol/L)                         0.84        0.16            0.0795 ± 0.0658    0.23            -0.4622 ± 0.2595   0.08            **0.04**
  **Triglyceride**                                                                                                                       
  Plasma (mmol/L)                      0.53        0.06            0.0443 ± 0.0680    0.52            0.3500 ± 0.1964    0.08            0.15
  VLDL (mmol/L)                        0.63        0.18            0.0079 ± 0.0668    0.91            0.2546 ± 0.1842    0.17            0.15
  **Apolipoproteins**                                                                                                                    
  Total-apoB (g/L)                     0.52        0.27            -0.1335 ± 0.0697   0.06            0.3271 ± 0.1635    **0.05**        **0.01**
  VLDL-apoB (g/L)                      0.71        0.37            -0.0428 ± 0.0768   0.59            0.2552 ± 0.2217    0.25            0.21
  LDL-apoB (g/L)                       0.47        0.28            -0.1174 ± 0.0718   0.10            0.3154 ± 0.1702    0.07            **0.02**
  apoA1 (g/L)                          0.08        0.94            0.2276 ± 0.0555    **\< 0.0001**   -0.2053 ± 0.2858   0.47            0.13
  **Ratios**                                                                                                                             
  Plasma-C/HDL-C                       0.72        0.11            -0.1757 ± 0.0795   **0.03**        0.5480 ± 0.2188    **0.01**        **0.003**
  VLDL-TG/VLDL-apoB (mmol/g)           0.87        0.80            0.0187 ± 0.0654    0.78            0.0446 ± 0.2425    0.85            0.92
  LDL-C/LDL-apoB (mmol/g)              0.38        **\< 0.0001**   -0.0070 ± 0.0774   0.93            -1.0577 ± 0.1644   **\< 0.0001**   **\< 0.0001**
  HDL-C/HDL-apoA1 (mmol/g)             0.28        **\< 0.0001**   -0.0834 ± 0.0655   0.21            -0.5382 ± 0.1381   **0.0002**      **0.004**

Values represent percentage of variance and *p*-values for each of the effects included in the model. See Materials and methods section for details. Significant results are highlighted in bold type.

Abbreviations: apo, apolipoprotein; BMI, body mass index; C, cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SE, standard error; TG, triglyceride; VLDL, very-low-density lipoprotein

###### 

*LIPE*C-60G and *LIPE*C-60G-physical activity interactions on body fat, and plasma lipid and lipoprotein concentrations in women from the Quebec Family Study

                                       C-60G   PA          C-60 by PA         G-60 by PA   Interaction                    
  ------------------------------------ ------- ----------- ------------------ ------------ ------------------ ----------- ----------
  **Body fat**                                                                                                            
  BMI (kg/cm^2^)                       0.88    **0.02**    -0.0526 ± 0.0640   0.41         -0.3013 ± 0.1333   **0.02**    0.09
  Fat mass (kg)                        0.60    **0.04**    -0.0883 ± 0.0665   0.19         -0.1864 ± 0.1136   0.10        0.46
  Percentage body fat (%)              0.41    **0.01**    -0.1117 ± 0.0574   **0.05**     -0.2261 ± 0.1178   0.06        0.38
  Abdominal visceral fat (cm^2^)       0.26    0.65        -0.0057 ± 0.0647   0.93         0.0591 ± 0.1315    0.65        0.72
  Abdominal subcutaneous fat (cm^2^)   0.67    **0.002**   -0.0925 ± 0.0607   0.13         -0.4103 ± 0.1457   **0.006**   **0.05**
  Abdominal total fat (cm^2^)          0.59    **0.003**   -0.0895 ± 0.0579   0.12         -0.4232 ± 0.1567   **0.008**   0.05
  **Cholesterol**                                                                                                         
  Plasma (mmol/L)                      0.48    0.40        -0.0847 ± 0.0807   0.30         -0.0624 ± 0.1529   0.68        0.90
  LDL (mmol/L)                         0.45    0.60        -0.0380 ± 0.0777   0.63         -0.0484 ± 0.1436   0.74        0.95
  HDL (mmol/L)                         0.66    0.17        -0.0548 ± 0.0608   0.37         -0.1158 ± 0.1147   0.31        0.65
  **Triglyceride**                                                                                                        
  Plasma (mmol/L)                      0.87    0.95        -0.0329 ± 0.0566   0.56         0.0411 ± 0.1313    0.76        0.62
  VLDL (mmol/L)                        0.95    0.56        -0.0453 ± 0.0592   0.45         -0.0538 ± 0.1602   0.74        0.96
  **Apolipoproteins**                                                                                                     
  Total-apoB (g/L)                     0.80    0.41        -0.0620 ± 0.0641   0.33         -0.0760 ± 0.1572   0.63        0.94
  VLDL-apoB (g/L)                      0.97    0.87        -0.0432 ± 0.0525   0.41         0.0153 ± 0.1603    0.92        0.73
  LDL-apoB (g/L)                       0.81    0.43        -0.0541 ± 0.0644   0.40         -0.0708 ± 0.1464   0.63        0.92
  apoA1 (g/L)                          0.79    0.82        -0.0252 ± 0.0641   0.69         -0.0046 ± 0.1233   0.97        0.89
  **Ratios**                                                                                                              
  Plasma-C/HDL-C                       0.96    0.99        -0.0362 ± 0.0682   0.84         -0.0137 ± 0.1601   0.93        0.88
  VLDL-TG/VLDL-apoB (mmol/g)           0.22    0.14        -0.0609 ± 0.0634   0.34         -0.2242 ± 0.1781   0.21        0.38
  LDL-C/LDL-apoB (mmol/g)              0.39    0.74        -0.0026 ± 0.0908   0.98         -0.0538 ± 0.1370   0.70        0.75
  HDL-C/HDL-apoA1 (mmol/g)             0.43    0.19        -0.0590 ± 0.0599   0.33         -0.1330 ± 0.1365   0.33        0.63

Values are percentage of variance and *p*-values for each effect included in the model. See Materials and methods section for details. Significant results are highlighted in bold type.

Abbreviations: apo, apolipoprotein; BMI, body mass index; C, cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SE, standard error; TG, triglyceride; VLDL, very-low-density lipoprotein

Except for BMI in men (*p*= 0.006), no evidence of association was observed between the *LIPE*C-60G polymorphism and adiposity or lipid and lipoprotein phenotypes in both men and women. In men, physical activity had a significant effect on fat mass (*p*= 0.02), percentage body fat (*p*= 0.04) and on LDL-C/LDL-apoB (*p*\< 0.0001) and HDL-C/apoA1 (*p*\< 0.0001) ratios. In women, physical activity had a significant effect on BMI (p = 0.02), fat mass (*p*= 0.04), percentage body fat (*p*= 0.01), abdominal subcutaneous fat (*p*= 0.002) and abdominal total fat (*p*= 0.003) areas, but no effect on lipid and lipoprotein phenotypes.

In men, we observed significant *LIPE*C-60G- physical activity interactions on BMI (*p*= 0.006), fat mass (*p*= 0.04), abdominal visceral fat area (*p*= 0.005), and on HDL-C (*p*= 0.04), total apoB (*p*= 0.01) and LDL-apoB (*p*= 0.02) concentrations, as well as on plasma cholesterol/HDL-C (*p*= 0.003), LDL-C/LDL-apoB (*p*\< 0.0001) and HDL-C/HDL-apoA1 (*p*= 0.004) ratios (Table [4](#T4){ref-type="table"}). As shown in Figure [1](#F1){ref-type="fig"}, in non-carriers of the *LIPE*G-60 variant, a high physical activity level is associated with lower BMI (low physical activity: 26.1 ± 0.7 kg/m^2^; high physical activity: 24.7 ± 0.7 kg/m^2^; *p*= 0.04), abdominal visceral fat (low physical activity: 151.1 ± 7.3 cm^2^; high physical activity: 138.9 ± 7.2 cm^2^; *p*= 0.04) and abdominal subcutaneous fat (low physical activity: 228.8 ± 15.8 cm^2^; high physical activity: 187.9 ± 14.8 cm^2^; *p*= 0.03). Such a beneficial effect of physical activity is not seen in carriers of the G-60 allele. Similarly, the beneficial effects of physical activity on the lipid profile was observed only in non-carriers of the variant, who exhibited reduced LDL-apoB values (low physical activity: 0.91 ± 0.02 g/L; high physical activity: 0.85 ± 0.02 g/L; *p*= 0.02), as well as a lower plasma cholesterol/HDL-C ratio (low physical activity: 4.98 ± 0.14; high physical activity: 4.57 ± 0.15; *p*= 0.02; Figure [1](#F1){ref-type="fig"}). In *LIPE*G-60 carriers, high level physical activity was associated with a higher BMI value (low physical activity: 22.7 ± 0.9 kg/m^2^; high physical activity: 24.4 ± 0.7 kg/m^2^; *p*= 0.04).

In women, a significant *LIPE*C-60G-physical activity interaction was observed for abdominal subcutaneous fat area (*p*= 0.05) (Table [5](#T5){ref-type="table"}). As shown in Figure [1](#F1){ref-type="fig"}, and unlike the results found in men, the beneficial effect of physical activity on adiposity in women was observed in carriers of the G-60 allele. Indeed, in women, a high physical activity level was associated with a lower BMI (low physical activity: 27.7 ± 1.9 kg/m^2^; high physical activity: 21.1 ± 1.5 kg/m^2^; *p*= 0.008; *LIPE*C-60G-physical activity interactions term: *p*= 0.09) and abdominal subcutaneous fat area (low physical activity: 411.3 ± 43.8 cm^2^; high physical activity: 237.1 ± 33.1 cm^2^; *p*= 0.007) in the G-60 carriers.

Discussion
==========

In the present study, we showed that the effects of physical activity on body fat and plasma lipid levels were influenced by *LIPE*C-60G polymorphism. In our study sample, the frequency of the *LIPE*G-60 allele (0.0503) was between the frequencies reported in the Baltic region of Europe (0.037) and southern Europe (0.087) \[[@B17]\]. It was also very close to the frequency observed in Caucasians of the HERITAGE Family Study (0.07) \[[@B13]\].

HSL is responsible for triglyceride mobilisation and is largely expressed in white adipose tissue, skeletal muscle and pancreatic β-cells \[[@B3]\] but does not appear to be the only enzyme responsible for fat mobilisation in adipose tissue. The role of HSL (as the rate-limiting enzyme for triglyceride mobilisation) has been questioned, since the publication of unexpected results from HSL^-/-^mice studies and the discovery of an adipose triglyceride lipase \[[@B1]\]. During a fasting state or moderate intensity exercise, the hormone-stimulated lipolytic pathway is activated as a result of a change in the balance between the stimulatory and inhibitory pathways of HSL activation. During moderate intensity exercise, lipid mobilisation is principally stimulated by an increase in catecholamine production, which stimulates lipolysis via β-adrenoceptors \[[@B6]\]. The situation seems to be different, however, in the adipose tissue of obese subjects. Indeed, in obese subjects, basal lipolysis and HSL activity are significantly decreased in abdominal subcutaneous fat after 12 weeks of exercise training, despite an increase in the β-adrenergic component, reflecting greater catecholamine sensitivity \[[@B33]\]. Finally, HSL expressed in skeletal muscle has been shown to be essential for intramuscular triacylglycerol hydrolysis during the first hour of moderate intensity exercise \[[@B7]\].

Our results demonstrated the presence of significant gene (*LIPE*C-60G)-physical activity interactions on body fat and plasma lipid and lipoprotein levels, particularly in men. The presence of this interactive effect suggests that the relationship between physical activity and body fat, as well as plasma lipids and lipoproteins, varies according to *LIPE*C-60G genotype. Indeed, male carriers of the *LIPE*G-60 allele did not appear to benefit as much from physical activity for body fat (BMI) and plasma lipid cardiovascular risk factors such as the plasma cholesterol/HDL-C ratio (Table [4](#T4){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). One explanation for this is that, compared with male non-carriers of the *LIPE*G-60 allele who have a lower BMI in the high physically active group than in the low physically active group (physical activity contributes to weight loss by stimulating lipid mobilisation), male carriers of the *LIPE*G-60 allele (an allele that confers a lower transcriptional activity \[[@B12],[@B14]\]) exhibit a higher BMI (lower lipid mobilisation) in the high physically active group than in the low physically active group. Thus, a lipid mobilisation defect in physically active carrier men contributes to a higher BMI, associated with lower HDL-C production and leading to a higher plasma cholesterol/HDL-C ratio. This is what we observed with the significant *LIPE*C-60G-physical activity interaction term on plasma cholesterol/HDL-C ratio (*p*= 0.003) (Figure [1](#F1){ref-type="fig"}), suggesting that, in men, it may be important to take this interaction effect into account for future *LIPE*C-60G association studies.

Women also exhibited significant gene (*LIPE*C-60G)-physical activity interactions for body fat phenotypes. By contrast with men, however, only female carriers of the *LIPE*G-60 allele appear to benefit from physical activity for BMI and abdominal subcutaneous fat (Figure [1](#F1){ref-type="fig"}). Indeed, female carriers of the *LIPE*G-60 allele in the high physical activity group exhibited a significantly lower BMI (*p*= 0.008) and abdominal subcutaneous fat area (*p*= 0.007) than carriers in the low physical activity group. These relationships between physical activity and body fat according to *LIPE*C-60G genotype were not affected by menopause (data not shown). We have previously shown that sedentary Caucasian women carrying the *LIPE*G-60 allele exhibited a lower percentage of fat and sum of eight skinfolds \[[@B13]\]. Thus, in the present study and in previous studies, we have observed that carriers of the *LIPE*G-60 allele exhibited reduced body fat in the subcutaneous compartment,\[[@B13]\] which is lowered in physically active women.

It has been suggested that the DNA sequence located between nucleotides -86 and -57 is necessary for the expression of HSL \[[@B34]\]. Moreover, the C-60G polymorphism has been shown to affect the expression of HSL in *in vitro*studies that showed that the genomic sequence (-86 to-85 bp upstream of the transcription start site) with the G-60 nucleotide inserted into a pGL3-Enhancer vector resulted in a 40 per cent lower luciferase activity compared with the wide-type -60C construct \[[@B12]\]. Unexpected results were observed in studies using *hsl*knockout mice, since these animals exhibited reduced adipose tissue \[[@B35]\] and mild hyperglycaemia \[[@B36]\] compared with wild-type mice. All together, these results suggest that a metabolic compensatory effect may occur in the absence of, or with reduced, HSL expression. From our results, we suspect that only female carriers of the -60G allele are probably able to counteract the lower HSL expression level, through metabolic compensation. Indeed, mice deficient in *hsl*in adipose tissue exhibited many metabolic adaptations,\[[@B35]\] including lower fatty acid *de novo*synthesis, which may explain the observed lower body fat in Caucasian women from the HERITAGE Family Study carriers of the *LIPE*G-60 allele. As physical activity promotes the mobilisation of fatty acids stored in adipose tissue, it is possible that such activity reinforces the metabolic compensation occurring when HSL expression level is low, resulting in a lower BMI and abdominal subcutaneous fat area in physically active female carriers of the *LIPE*G-60 allele. No effects were observed for plasma lipid and lipoprotein concentrations in women.

Since this study is the first to demonstrate a gene-physical activity interaction on body fat and plasma lipid and lipoprotein concentrations using the *LIPE*C-60G polymorphism, these results need to be replicated. Although multiple statistical tests have been performed, thus highlighting the chance for obtaining spurious significant association gene-physical activity interaction with BMI (*p*= 0.006), fat mass (*p*= 0.04), abdominal visceral fat (*p*= 0.005) and plasma cholesterol/HDL-C ratio (*p*= 0.003) in men, and with abdominal subcutaneous fat (*p*= 0.005) and abdominal total fat (*p*= 0.05) in women are strong enough to be considered as significant. Finally, the physical activity score used in the present study has been demonstrated in other studies to be characterised by good reproducibility and to be well correlated with parameters of physical fitness \[[@B37]\].

In summary, this study tested for *LIPE*G-60C- physical activity interactions on body fat and plasma lipid and lipoprotein levels in the QFS cohort. In men, significant *LIPE*C-60G-physical activity interactions were observed for BMI, abdominal visceral fat area and plasma cholesterol/HDL-C ratio, whereas in women an interaction was observed only for abdominal subcutaneous fat area. These observations emphasise the importance of taking into account gene-physical activity interactions in association studies involving candidate genes for obesity and obesity-related traits. It would be useful to verify these observational data in a controlled exercise intervention study.
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